RNS Number : 3763K
Pharma C Investments PLC
20 December 2022

20 December 2022

Pharma C Investments PLC

("Pharma C" or the "Company")

Result of Annual General Meeting

Pharma C Investments (AQSE: PCIL), an early-stage investor and venture builder in the medical cannabis industry with a particular focus on companies that provide ancillary products and services to the medicinal cannabis sectors, announces that at the Annual General Meeting of the Company ("AGM") held at 11 a.m. today, resolutions 1, 2 and 3, as set out in the notice of AGM posted to shareholders on 24 November, were passed, and resolutions 4, 5 and 6.1 to 6.4 were rejected.

Following the AGM, Sharon Segal and Toby Shillito are therefore no longer directors of the Company. The Company will appoint at least one other director as soon as is practically possible.

The Director of the Company accepts responsibility for the contents of this announcement.

This announcement contains inside information for the purposes of Article 7 of the EU Regulation 596/2014 as it forms part of the UK law by virtue the European Union (Withdrawal) Act 2018

For further information please visit www.pharmacinvestments.com

For additional information please contact:

Pharma C Investments

Gavin Sathianathan, Investment Strategy Director

gavin@pharmacinvestments.com

Novum Securities (AQSE Corporate Adviser)

Tel: +44 207 399 9400

David Coffman

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services.

For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXFLFFRFTLIFIF